Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 7/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.41 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.41 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.41 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.41 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.41 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.41 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 7/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17514146 | 0.98 | L3MBTL1 (0.48) | L3MBTL1CHRNB2CHRNA7CHRNA4PARP1 | |
| SCHEMBL2707264 | 0.95 | L3MBTL1 (0.44) | L3MBTL1CHRNB2CHRNA7CHRNA4PARP1 | |
| SCHEMBL166889 | 0.87 | L3MBTL1 (0.49) | L3MBTL1CHRNB2CHRNA7CHRNA4PARP1 | |
| SCHEMBL6177583 | 0.87 | L3MBTL1 (0.49) | L3MBTL1CHRNB2CHRNA7CHRNA4PARP1 | |
| SCHEMBL30504206 | 0.84 | L3MBTL1 (0.53) | L3MBTL1CHRNB2CHRNA7CHRNA4PARP1 | |
| SCHEMBL1713225 | 0.84 | L3MBTL1 (0.53) | L3MBTL1CHRNB2CHRNA7CHRNA4PRKAB2 | |
| SCHEMBL30139646 | 0.84 | L3MBTL1 (0.53) | L3MBTL1CHRNB2CHRNA7CHRNA4PRKAB2 | |
| SCHEMBL3330878 | 0.84 | L3MBTL1 (0.53) | L3MBTL1CHRNB2CHRNA7CHRNA4PARP1 | |
| SCHEMBL6178580 | 0.84 | L3MBTL1 (0.53) | L3MBTL1CHRNB2CHRNA7CHRNA4PRKAB2 | |
| SCHEMBL6179869 | 0.84 | L3MBTL1 (0.53) | L3MBTL1CHRNB2CHRNA7CHRNA4PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3943491-A1 | HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT | Voronoi Inc. (KR) | 2022-01-26 | — | — | EP | disclosed |
| EP-3183239-B1 | INDAZOLES | MERCK PATENT GMBH (DE) | 2018-09-26 | — | — | EP | disclosed |
| US-9862717-B2 | Indazoles | MERCK PATENT GMBH (DE) | 2018-01-09 | — | — | US | disclosed |
| US-9862717-B2 | Indazoles | MERCK PATENT GMBH (DE) | 2018-01-09 | — | — | US | disclosed |
| US-20170267675-A1 | INDAZOLES | MERCK PATENT GMBH (DE) | 2017-09-21 | — | — | US | disclosed |
| US-20170267675-A1 | INDAZOLES | MERCK PATENT GMBH (DE) | 2017-09-21 | — | — | US | disclosed |
| US-20170267675-A1 | INDAZOLES | MERCK PATENT GMBH (DE) | 2017-09-21 | — | — | US | disclosed |
| WO-2016026549-A1 | INDAZOLES | MERCK PATENT GMBH (DE) | 2016-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267675-A1 | INDAZOLES | MKI67, CCNI, BRCA1 | L3MBTL1 2666/4885CHRNB2 4688/4885CHRNA7 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.